Paul S. Aisen

This study tests a vaccine called AADvac1, which targets tau tangles in the brain, a hallmark of Alzheimer's. It will be given alone or with another drug (donanemab) to 450 adults aged 50-80 with very early Alzheimer's. The goal is to see if this approach can reduce tau buildup a…

This study tests whether drugs that target tau protein, alone or with donanemab, can reduce tau buildup and slow memory decline in people aged 50-80 with early Alzheimer's. Participants will receive treatment for 30 months and undergo brain scans and cognitive tests. The goal is …